IDH2 and central nervous system cancer: The 1p/19q non−codel, IDH-wildtype, classical and mesenchymal subtype, MGMT promotor unmethylated, and higher WHO grade, which are the malignant clinicopathological features in glioma (Verhaak et al., 2010; Weller et al., 2012), were associated with a higher risk score.